Stock Watch: Donanemab Provides Cover For Lilly’s Second-Quarter Insulin Challenge
An Accelerated Approval Tomorrow Trumps Biosimilar Competition Today
Executive Summary
Lilly’s second-quarter earnings announcement relegated its core business in favor of its experimental Alzheimer’s disease drug. This diverted attention away from competitive reimbursement challenges that may be affecting its insulin business.